文献速递肝病消化道肿瘤与早癌

病毒复制活性与HBV相关肝细胞癌术后复发的关联

Association Between Viral Replication Activity and Postoperative Recurrence of HBV-Related Hepatocellular Carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2025-03-16

这项跨国回顾性队列纳入2384例极早期或早期HBV相关肝细胞癌患者,均接受治愈性切除和抗病毒治疗。中位随访4.9年,49.8%复发。持续抗病毒治疗组与起始抗病毒治疗组总体复发风险相似(HR 1.09),但肝硬化患者中起始组复发风险更高(HR 1.22),非肝硬化起始组中基线HBV DNA 5-6 log10 IU/mL者复发风险显著高于持续组(HR 1.78)。

要点

  • 总体持续与起始抗病毒治疗组复发风险相似(HR 1.09,95%CI 0.96-1.24)。
  • 肝硬化患者中起始抗病毒治疗组复发风险高于持续组(HR 1.22,95%CI 1.02-1.45)。
  • 非肝硬化起始组基线HBV DNA 5-6 log10 IU/mL者复发风险高于持续组(HR 1.78)。

核心结论

  • HBV复制活性与肝细胞癌复发风险的关联因是否合并肝硬化而异,为优化抗病毒治疗时机和术后监测策略提供依据。

研究设计与样本

  • 跨国回顾性队列研究,纳入2010至2018年间连续接受治愈性切除并接受抗病毒治疗的极早期或早期HBV相关肝细胞癌患者2384例。
  • 患者分为持续抗病毒治疗组(既往已抗病毒且病毒抑制)和起始抗病毒治疗组(切除时开始抗病毒治疗)。

主要发现

  • 中位随访4.9年,1188例(49.8%)发生复发。
  • 多因素分析显示持续抗病毒治疗组与起始抗病毒治疗组复发风险相似(HR 1.09,95%CI 0.96-1.24)。
  • 肝硬化患者中起始抗病毒治疗组复发风险高于持续组(HR 1.22,95%CI 1.02-1.45),非肝硬化患者中无此差异(HR 0.90,95%CI 0.73-1.09)。
  • 非肝硬化起始抗病毒治疗组中,基线HBV DNA 5-6 log10 IU/mL者复发风险显著高于持续组(HR 1.78,95%CI 1.32-2.42)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Baseline viral replication activity influences the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B virus (HBV) infection. AIMS: To evaluate the impact of baseline viral replication activity on recurrence in HBV-related HCC after curative resection. METHODS: A multinational retrospective cohort of 2384 patients with very early or early-stage HBV-related HCC who consecutively underwent curative resection and received antiviral therapy (AVT) between 2010 and 2018 was analysed. Patients were categorised into ongoing-AVT (previously on AVT with viral suppression) and initiation-AVT (initiated AVT at the time of resection) groups. HCC recurrence was compared between these two groups based on baseline viral replication activity. RESULTS: During a median follow-up of 4.9 years, 1188 (49.8%) patients developed recurrence. Multivariable analysis showed similar recurrence risk between the ongoing-AVT and initiation-AVT groups (HR, 1.09; 95% CI, 0.96-1.24). However, in cirrhotic patients, the initiation-AVT group had a higher recurrence risk than the ongoing-AVT group (HR, 1.22; 95% CI, 1.02-1.45) but not in non-cirrhotic patients (HR, 0.90; 95% CI, 0.73-1.09). Intriguingly, in the non-cirrhotic initiation-AVT group, a parabolic association was observed between baseline HBV DNA levels and the risk of recurrence, with those having 5-6 log10 IU/mL HBV DNA levels showing significantly higher recurrence risk compared to the ongoing-AVT group (HR, 1.78; 95% CI, 1.32-2.42). CONCLUSIONS: The association between HBV replication activity and the risk of HCC recurrence varied depending on cirrhosis, providing important insights for optimising the timing of AVT and post-operative surveillance strategies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Heo S, Yang J, Park J, et al. Association Between Viral Replication Activity and Postoperative Recurrence of HBV-Related Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2025. PMID: 40091291. doi:10.1111/apt.70085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。